In conclusion, current HF management, alongside imaging techniques, incorporates four key classes of soluble biomarkers strongly recommended by the 2023 ESC and 2022 AHA/ACC/HFSA guidelines: NPs, Gal-3, sST2, hs-TnT/I, each reflecting distinct pathophysiological processes (Figure 1); below, we provide a concise overview of these biomarkers (reviewed in [44]). The gene discussed is LGALS3; the disease is hydrops fetalis.